Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06124300 · ClinicalTrials.gov registry record · NA

Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome

A NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome, sponsored by Rael.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06124300 is a NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome that has completed, run by Rael. The registered enrollment target is 40 participants, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06124300, a NA study of Polycystic Ovary Syndrome and Premenstrual Syndrome, has completed, sponsored by Rael.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a virtual single group study that will last 12 weeks. Participants will take 1 scoop of the female hormone balance supplement, and mix it with their drink of choice every morning. Questionnaires will be completed at baseline, 1 week, 2 weeks, 4 weeks, and 12 weeks

Interventions

  • DIETARY_SUPPLEMENT Female Hormone Balance Supplement

Study Locations (1)

California

  • Citruslabs - Santa Monica

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-08-30
Est. Completion 2024-01-19
Phase NA

Sponsor

Rael

5 total trials

What the Registry Record Tells You About NCT06124300

The ClinicalTrials.gov registry entry for NCT06124300 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 17,257-participant average among 30 other Polycystic Ovary Syndrome trials with a reported enrollment target (100% lower). The listed sponsor is Rael, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Polycystic Ovary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Female Hormone Balance Supplement is the first listed.

NCT06124300 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06124300 about?

NCT06124300 is a clinical study titled "Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome". This is a virtual single group study that will last 12 weeks. Participants will take 1 scoop of the female hormone balance supplement, and mix it with their drink of choice every morning. Questionnaires will be completed at baseline, 1 week, 2 weeks, 4 weeks, and 12 weeks

What is the current status of trial NCT06124300?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2023-08-30. Estimated completion is 2024-01-19.

What conditions does trial NCT06124300 study?

This clinical trial studies the following conditions: Polycystic Ovary Syndrome, Premenstrual Syndrome.

What interventions are being tested in trial NCT06124300?

The interventions under investigation include: Female Hormone Balance Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06124300?

This trial is sponsored by Rael, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06124300 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Polycystic Ovary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.